These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38761779)

  • 1. TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin.
    Wu J; Jiang L; Wang S; Peng L; Zhang R; Liu Z
    Int Immunopharmacol; 2024 Jun; 134():112235. PubMed ID: 38761779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Choi HJ; Heo JH; Park JY; Jeong JY; Cho HJ; Park KS; Kim SH; Moon YW; Kim JS; An HJ
    Gynecol Oncol; 2019 Apr; 153(1):135-148. PubMed ID: 30686552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RY-2f, an isoflavone analog, overcomes cisplatin resistance to inhibit ovarian tumorigenesis via targeting the PI3K/AKT/mTOR signaling pathway.
    Liu M; Qi Z; Liu B; Ren Y; Li H; Yang G; Zhang Q
    Oncotarget; 2015 Sep; 6(28):25281-94. PubMed ID: 26325371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.
    Santiskulvong C; Konecny GE; Fekete M; Chen KY; Karam A; Mulholland D; Eng C; Wu H; Song M; Dorigo O
    Clin Cancer Res; 2011 Apr; 17(8):2373-84. PubMed ID: 21372221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LDLR promotes autophagy-mediated cisplatin resistance in ovarian cancer associated with the PI3K/AKT/mTOR signaling pathway.
    Liu L; Sun YH; An R; Cheng RJ; Li N; Zheng JH
    Kaohsiung J Med Sci; 2023 Aug; 39(8):779-788. PubMed ID: 37218642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
    Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
    Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polypeptide LTX-315 reverses the cisplatin chemoresistance of ovarian cancer cells via regulating Beclin-1/PI3K/mTOR signaling pathway.
    Ma J; Liu L; Ling Y; Zheng J
    J Biochem Mol Toxicol; 2021 Sep; 35(9):e22853. PubMed ID: 34309113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of PI3K/AKT/mTOR signaling axis by UBE2S inhibits autophagy leading to cisplatin resistance in ovarian cancer.
    Zhang M; Wang J; Guo Y; Yue H; Zhang L
    J Ovarian Res; 2023 Dec; 16(1):240. PubMed ID: 38115063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PI3K/Akt/mTOR pathway-mediated macrophage autophagy in affecting the phenotype transformation of lung fibroblasts induced by silica dust exposure.
    DU Y; Huang F; Guan L; Zeng M
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Aug; 48(8):1152-1162. PubMed ID: 37875355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Label-free-based quantitative proteomic analysis of the inhibition of cisplatin-resistant ovarian cancer cell proliferation by cucurbitacin B.
    Yin S; Mai Z; Liu C; Xu L; Xia C
    Phytomedicine; 2023 Mar; 111():154669. PubMed ID: 36681055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.
    Ma H; Li Y; Wang X; Wu H; Qi G; Li R; Yang N; Gao M; Yan S; Yuan C; Kong B
    Cell Death Dis; 2019 Feb; 10(3):166. PubMed ID: 30778048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-497 decreases cisplatin resistance in ovarian cancer cells by targeting mTOR/P70S6K1.
    Xu S; Fu GB; Tao Z; OuYang J; Kong F; Jiang BH; Wan X; Chen K
    Oncotarget; 2015 Sep; 6(28):26457-71. PubMed ID: 26238185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Icariin enhances the chemosensitivity of cisplatin‑resistant ovarian cancer cells by suppressing autophagy via activation of the AKT/mTOR/ATG5 pathway.
    Jiang S; Chang H; Deng S; Fan D
    Int J Oncol; 2019 Jun; 54(6):1933-1942. PubMed ID: 31081049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Platinum Nanoclusters Activate PI3K/AKT/mTOR Signaling Pathway-Mediated Autophagy for Cisplatin-Resistant Ovarian Cancer Therapy.
    Zhang M; Yue H; Huang X; Wang J; Li Z; Deng X
    ACS Appl Mater Interfaces; 2022 Nov; 14(43):48502-48514. PubMed ID: 36261925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
    Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
    Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.
    Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
    Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
    Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.